Teleflex Incorporated

Report azionario NYSE:TFX

Capitalizzazione di mercato: US$6.0b

Teleflex Crescita futura

Criteri Future verificati 3/6

Si prevede che Teleflex aumenterà gli utili e i ricavi rispettivamente del 93% e 5.4% all'anno, mentre si prevede che l'EPS crescerà del 73.4% all'anno.

Informazioni chiave

93.0%

Tasso di crescita degli utili

73.38%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavi5.4%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento15 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Aug 04

Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates

Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...

Recent updates

Aggiornamento della narrazione • May 02

TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile

Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.
Aggiornamento della narrazione • Apr 17

TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside

Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.
Aggiornamento della narrazione • Apr 03

TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook

Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.
Aggiornamento della narrazione • Mar 20

TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook

Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.
Aggiornamento della narrazione • Mar 06

TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality

Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.
Aggiornamento della narrazione • Feb 20

TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook

Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.
Aggiornamento della narrazione • Feb 06

TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook

Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.
Aggiornamento della narrazione • Jan 23

TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook

Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.
Aggiornamento della narrazione • Jan 09

TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook

Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).
Aggiornamento della narrazione • Dec 20

TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds

Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.
Seeking Alpha • Dec 10

Teleflex: Selling, But How Much?

Summary Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures. I maintain a cautious long position, closely monitoring Q4 results to clarify divestment implications and future margin trajectory. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Dec 06

TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook

Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.
Aggiornamento della narrazione • Nov 22

TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures

Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.
Articolo di analisi • Nov 09

Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34

Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...
Aggiornamento della narrazione • Nov 07

TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside

Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.
Articolo di analisi • Oct 30

Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing

Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...
Articolo di analisi • Sep 11

These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Aggiornamento della narrazione • Aug 29

Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.
Articolo di analisi • Aug 04

Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates

Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...
Articolo di analisi • Aug 03

Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34

Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...
Articolo di analisi • Jul 10

Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing

With a price-to-earnings (or "P/E") ratio of 35.1x Teleflex Incorporated ( NYSE:TFX ) may be sending very bearish...
Articolo di analisi • Jun 22

Investors Met With Slowing Returns on Capital At Teleflex (NYSE:TFX)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
Seeking Alpha • Mar 02

Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation

Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Teleflex Incorporated: Compelling Only On One Metric

Summary Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest price-to-sales ratio in a decade. Have the shares fallen into the 'buy zone'?  An analysis of Teleflex Incorporated follows in the paragraphs below. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:TFX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20282,5191932911367
12/31/20272,4001413256711
12/31/20262,288-410815211
3/31/20262,1271227317N/A
12/31/20251,99359245341N/A
9/28/20251,556-384306391N/A
6/29/20251,407136438514N/A
3/30/20251,37694522598N/A
12/31/20241,70057545636N/A
9/29/20243,026238450572N/A
6/30/20243,008265417543N/A
3/31/20243,001296430538N/A
12/31/20231,712144464511N/A
10/1/20232,959405381471N/A
7/2/20232,899369326412N/A
4/2/20232,860363278366N/A
12/31/20222,791363264344N/A
9/25/20222,795412373445N/A
6/26/20222,808510421488N/A
3/27/20222,817488537603N/A
12/31/20212,810485580651N/A
9/26/20212,759434565645N/A
6/27/20212,687351479567N/A
3/28/20212,540280468559N/A
12/31/20202,537336346436N/A
9/27/20202,507367307389N/A
6/28/20202,527479327413N/A
3/29/20202,612551N/A364N/A
12/31/20192,595462N/A440N/A
9/29/20192,556442N/A427N/A
6/30/20192,517269N/A416N/A
3/31/20192,475183N/A415N/A
12/31/20182,448196N/A437N/A
9/30/20182,40266N/A404N/A
7/1/20182,32789N/A404N/A
4/1/20182,246170N/A416N/A
12/31/20172,146155N/A420N/A
10/1/20172,065259N/A427N/A
7/2/20171,986246N/A425N/A
4/2/20171,931227N/A432N/A
12/31/20161,868237N/A408N/A
9/25/20161,828267N/A426N/A
6/26/20161,816262N/A373N/A
3/27/20161,795248N/A326N/A
12/31/20151,799236N/A301N/A
9/27/20151,798197N/A255N/A
6/28/20151,808191N/A276N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di TFX ( 93% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di TFX ( 93% all'anno) cresceranno più rapidamente del mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di TFX cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di TFX ( 5.4% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di TFX ( 5.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TFX è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 14:57
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Teleflex Incorporated è coperta da 26 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Matthew TaylorBarclays
Travis SteedBofA Global Research
Travis SteedBofA Global Research